Experience with Exemestane in the Treatment of Early and Advanced Breast Cancer

Expert Opinion on Drug Metabolism and Toxicology

Volumn 4, Issue 7, 2008, Pages 987-997

  Lønning, Per Eystein ^a   Geisler, Jürgen ^b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Aromatase inhibitor; Breast cancer; Estrogen; Exemestane

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; ESTRADIOL; EXEMESTANE; FADROZOLE; FORMESTANE; KETOCONAZOLE; LETROZOLE; MEGESTROL ACETATE; PLACEBO; PYRIDOGLUTETHIMIDE; TAMOXIFEN; VOROZOLE;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; BONE DENSITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CLINICAL TRIAL; CROSS RESISTANCE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG STRUCTURE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EARLY CANCER; ENZYME INHIBITION; ESTRADIOL BLOOD LEVEL; FOOD; FOOD DRUG INTERACTION; FRACTURE; HEALTH CARE COST; HUMAN; METABOLIC DISORDER; METASTASIS; MONOTHERAPY; MYALGIA; NONHUMAN; OSTEOLYSIS; POSTMENOPAUSE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; TENDON DISEASE;

ANDROSTADIENES; ANIMALS; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASM METASTASIS;

EID: 49649112422     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.4.7.987     Document Type: Review

References (119)

1. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma. Suggestions for a new method of treatment with illustrative cases. Lancet 1896;2:104-7
2. Luft R, Olivecrona H, Sjögren B. Hypophysektomy in man. Nord Med 1952;14:351-4
3. Dao TL, Huggins C. Bilateral adrenalectomy in the treatment of cancer of the breast. Arch Surg 1955;71:645-57
4. Haddow A, Watkinson JM, Paterson E. Influence of synthetic oestrogens upon advanced malignant disease. Brit Med J 1944;2:393-8
5. Binnie GG. Regression of tumors following treatment by stilboestrol and x-ray therapy, with notes on case of breast tumour which regressede with stilboestrol alone. Brit J Radiol 1944;17:42-5
6. Kennedy BJ, Nathanson IT. Effects of intensive sex steroid hormone therapy in advanced breast cancer. JAMA 1953;152:1135-41
7. Taylor SG, Ayer JP, Morris RS. Cortical steroids in treatment of cancer. JAMA 1956;144(13):1058-64
8. Kofman S, Nagamani D, Buenger RF, Taylor SG. The use of prednisolone in the treatment of disseminated breast carcinoma. Cancer 1958;11(1):226-32
9. NissenMeyer R, Vogt JH. Cortisone treatment of metastatic breast cancer. Acta Unio Int Contra Cancrum 1959;15:1140-4
10. Nosaquo ND. Androgens and estrogens in the treatment of disseminated mammary carcinoma. JAMA 1960;172:135-47
11. Volk H, Deupree RH, Goldenberg IS, et al. A dose response evaluation of delta-1-testololactone in advanced breast cancer. Cancer 1974;33:9-13
12. Geisler J, Lønning PE. Aromatase inhibition - translation into a successful therapeutic approach. Clin Cancer Res 2005;11:2809-21
13. Brodie AMH, Schwarzel WC, Shaikh AA, Brodie Hj. The effect of an aromatase inhbitor, 4-hydroxy-androstene-3,17-dione, on estrogen-dependent processes in reproduction and breast cancer. Endocrinology 1977;100:1684-95
14. Brodie AMH, Marsh D, Brodie HJ. Aromatase inhibitors-IV.regression of hormone-dependent, mammary tumors in the rat with 4-acetoxy-4-androstene-3, 17-dione. J Steroid Biochem 1979;10:423-9
15. Brodie AMH, Longcope C. Inhibition of peripheral aromatization by aromatase inhibitors, 4-hydroxy- and 4-acetoxy-androstene-3,17-dione. Endocrinology 1980;106(1):19-21
16. Brodie AMH, Garrett WM, Hendrickson JR, et al. Robinson CH. Inactivation of aromatase in vitro by 4-hydroxy-4-androstene-3,17-dione and 4-acetoxy-4-androstene-3,17-dione and sustained effects in vivo. Steroids 1981;38:693-702
17. Coombes RC, Goss P, Dowsett M, et al. 4-hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer. Lancet 1984;ii:1237-9
18. Dowsett M, Cunningham DC, Stein RC, et al. Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients. Cancer Res 1989;49:1306-12
19. Dowsett M, Mehta A, King N, et al. An endocrine and pharmacokinetic study of four oral doses of formestane in postmenopausal breast cancer patients. Eur J Cancer 1992;28:415-20
20. Jones AL, MacNeill F, Jacobs S, et al. The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients. Eur J Cancer 1992;28A:1712-6
21. MacNeill FA, Jacobs S, Dowsett M, et al. The effects of oral 4-hydroxyandrostenedione on peripheral aromatisation in post-menopausal breast cancer patients. Cancer Chemother Pharmacol 1995;36:249-54
22. Lønning PE, Geisler J, Johannessen DC, et al. Pharmacokinetics and metabolism of formestane in breast cancer patients. J Steroid Biochem Mol Biol 2001;77(1):39-47
23. Hughes SWM, Burley DM. Aminoglutethimide a "side-effect" turned to therapeutic advantage. Postgrad Med J 1970;46:409-16
24. Camacho AM, Cash R, Brough AJ, Wilroy PS. Inhibition of adrenal steroidogenesis by amino-glutethimide and mechanism of action. JAMA 1967;202(1):114-20
25. Cash R, Brough AJ, Cohen MNP, Satoh PS. Aminoglutethimide (Elipten-Ciba) is an inhibitor of adrenal steroidogenesis: mechanism of action and therapeutic trial. J Clin Endocrinol Metab 1967;27:1239-48
26. Santen RJ, Lipton A, Kendall J. Successful medical adrenalectomy with aminoglutethimide. JAMA 1974;230(12):1661-5
27. Santen RJ, Worgul TJ, Lipton A, et al. Aminoglutethimide as treatment of postmenopausal women with advanced breast carcinoma. Ann Intern Med 1982;96:94-101
28. Samojlik E, Santen RJ, Wells SA. Adrenal suppression with aminoglutethimide. II. Differential effects of aminoglutethimide on plasma androstenedione and estrogen levels. J Clin Endocrinol Metab 1977;45:480-7
29. Samojlik E, Veldhuis JD, Wells SA, Santen RJ. Preservation of androgen secretion during estrogen suppression with aminoglutethimide in the treatment of metastatic breast carcinoma. J Clin Invest 1980;65:602-12
30. Santen RJ, Santner S, Davis B, et al. Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma. J Clin Endocrinol Metab 1978;47:1257-65
31. Barone RM, Shamonki IM, Siiteri PK, Judd HL. Inhibition of peripheral aromatization of androstenedione to estrone in postmenopausal women with breast cancer using D1-testoloclactone. J Clin Endocrinol Metab 1979;49:672-6
32. Lønning PE. Pharmacology of new aromatase inhibitors. Breast 1996;5:202-8
33. Dowsett M, MacNeill F, Mehta A, et al. Endocrine, pharmacokinetic and clinical studies of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione ('pyridoglutethimide') in postmenopausal breast cancer patients. Br J Cancer 1991;64:887-94
34. MacNeill FA, Jones AL, Jacobs S, et al. The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer. Br J Cancer 1992;66:692-7
35. Lønning PE, Jacobs S, Jones A, et al. The influence of CGS 16949A on peripheral aromatisation in breast cancer patients. Br J Cancer 1991;63:789-93
36. Lønning PE. Aromatase inhibitors in breast cancer. End Rel Cancer 2004;11:179-89
37. Giudici D, Ornati C, Briatico G, et al. 6-Methylenandrosta-1,4-diene-3,17-dione (FCE 24304): a new irreversible aromatase inhibitor. J Steroid Biochem 1988;30:391-4
38. Di Salle E, Briatico C, Giudici D, et al. Aromatase inhibition and experimental antitumor activity of fce 24304, mdl 18962 and sh 489. J Steroid Biochem 1989;34(1-6):431-4
39. Di Salle E, Ornati G, Giudici D, et al. Exemestane (FCE 24304), a new steroidal aromatase inhibitor. J Steroid Biochem Mol Biol 1992;43:137-43
40. Di Salle E, Ornati G, Paridaens R, et al. Preclinical and clinical pharmacology of the aromatase inhibitor exemestane (FCE 24304). In: Motta M, Serio M, editors, Sex hormones and antihormones in endocrine dependent pathology. Elsevier Science, Amsterdam; 1994. p. 303-10
41. Hong YY, Yu B, Sherman M, et al. Molecular basis for the aromatization reaction and exemestane-mediated irreversible inhibition of human aromatase. Mol Endocrinol 2007;21(2):401-14
42. Zaccheo T, Giudici D, Ornati G, et al. Comparison of the effects of the irreversible aromatase inhibitor exemestane with atamestane and MDL 18962 in rats with DMBA-induced mammary tumours. Eur J Cancer 1991;27:1145-50
43. Zaccheo T, Salle ED. Effect of the irreversible aromatase inhibitor FCE 24304 on DMBA-induced mammary tumors in ovariectomized rats treated with testosterone. Cancer Chemother Pharmacol 1989;25:95-8
44. Wang X, Chen SU. Aromatase destabilizer: Novel action of exemestane, a food and drug administration-approved aromatase inhibitor. Cancer Res 2006;66(21):10281-6
45. Hong Y, Cho M, Yuan YC, Chen S. Molecular basis for the interaction of four different classes of substrates and inhibitors with human aromatase. Biochem Pharmacol 2008;75(5):1161-9
46. Breda M, Pianezzola E, Benedetti MS. Determination of exemestane, a new aromatase inhibitor, in plasma by high-performance liquid chromatography with ultraviolet detection. J Chromatogr 1993;620:225-31
47. Allievi C, Zugnoni P, Benedetti MS, Dostert P. Determination of plasma-levels of exemestane (FCE-24304), a new irreversible aromatase inhibitor, using thermospray liquid-chromatography mass-spectrometry. J Mass Spectrom 1995;30(5):693-7
48. Cenacchi V, Baratte S, Cicioni P, et al. LC-MS-MS determination of exemestane in human plasma with heated nebulizer interface following solid-phase extraction in the 96 well plate format. J Pharmaceut Biomed Anal 2000;22(3):451-60
49. Persiani S, Broutin F, Cicioni P, Benedetti MS. Determination of the new aromatase inhibitor exemestane in biological fluids by automated high-performance liquid chromatography followed by radioimmunoassay. Eur J Pharm Sci 1996;4(6):331-40
50. Persiani S, Poggesi I, Cicioni P, Benedetti MS. Pharmacokinetics of repeated low-doses of exemestane (1,2.5, 5, and 10 mg) in postmenopausal healthy volunteers [abstract 952]. Eur J Cancer 1995;031A:S198
51. Valle M, Di Salle E, Jannuzzo MG, et al. A predictive model for exemestane pharmacokinetics/pharmacodynamics incorporating the effect of food and formulation. Br J Clin Pharmacol 2005;59(3):355-64
52. Spinelli R, Jannuzzo MG, Poggesi I, et al. Pharmacokinetics (PK) of Aromasin(R) (exemestane, EXE) after single and repeated doses in healthy postmenopausal volunteers (HPV) [abstract 1185]. Eur J Cancer 1999;35:S295
53. Mauras N, Lima J, Patel D, et al. Pharmacokinetics and dose finding of a potent aromatase inhibitor, Aromasin (exemestane), in young males. J Clin Endocrinol Metab 2003;88(12):5951-6
54. Jannuzzo MG, Poggesi I, Spinelli R, et al. The effects of degree of hepatic or renal impairment on the pharmacokinetics of exemestane in postmenopausal women. Cancer Chemother Pharmacol 2004;53(6):475-81
55. Rivera E, Valero V, Francis D, et al. Pilot study evaluating the pharmacokinetics, pharmacodynamics, and safety of the combination of exemestane and tamoxifen. Clin Cancer Res 2004;10(6):1943-8
56. Hutson PR, Love RR, Havighurst TC, et al. Effect of exemestane on tamoxifen pharmacokinetics in postmenopausal women treated for breast cancer. Clin Cancer Res 2005;11(24):8722-7
57. Jannuzzo MG, Spinelli R, Poggesi I, et al. Inhibition of CYP3A4 does not influence Aromasin(R) (exemestane, EXE) pharmacokinetics (PK) in healthy postmenopausal volunteers (HPV) [abstract 1184]. Eur J Cancer 1999;35:S294
58. Evans TRJ, Salle ED, Omati G, et al. Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. Cancer Res 1992;52:5933-9
59. Johannessen DC, Engan T, Salle Ed, et al. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: A phase I study. Clin Cancer Res 1997;3:1101-8
60. Geisler J, Ekse D, Helle H, et al. An optimized, highly sensitive radioimmunoassay for the simultaneous measurement of estrone, estradiol and estrone sulfate in the ultra-low range in human plasma samples. J Steroid Biochem Mol Biol 2008
61. Lønning PE, Dowsett M, Powles TJ. Postmenopausal estrogen synthesis and metabolism: Alterations caused by aromatase inhibitors used for the treatment of breast cancer. J Steroid Biochem 1990;35:355-66
62. Lønning PE, Skulstad P, Sunde A, Thorsen T. Separation of urinary metabolites of radiolabelled estrogens in man by HPLC. J Steroid Biochem 1989;32:91-7
63. Jacobs S, Lønning PE, Haynes B, et al. Measurement of aromatisation by a urine technique suitable for the evaluation of aromatase inhibitors in vivo. J Enzyme Inhibition 1991;4:315-25
64. Geisler J, King N, Anker G, et al. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res 1998;4:2089-93
65. Geisler J, King N, Dowsett M, et al. Influence of anastrozole (Arimidex®), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br J Cancer 1996;74:1286-91
66. Geisler J, Haynes B, Anker G, et al. Influence of letrozole (Femara) and anastrozole (Arimidex) on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over-designed study. J Clin Oncol 2002;20:751-7
67. Thürlimann B, Paridaens R, Senn D, et al. Third line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicenter multinational study [abstract 527]. ASCO Abstr 1997;16:151a
68. Lønning PE, Bajetta E, Murray R, et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: A phase II trial. J Clin Oncol 2000;18(11):2234-44
69. Iaffaioli R, Formato R, Tortoriello A, et al. Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer. Br J Cancer 2005;92(9):1621-5
70. Bertelli G, Garrone O, Merlano M, et al. Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer. Oncology 2005;69(6):471-7
71. Mayordomo J, Llombart A, Martin M, et al. Randomized, multicenter, crossover phase II trial to compare exemestane (E) vs. anastrozole (A) in postmenopausal patients (pt) with advanced breast cancer (ABC) and positive hormone receptors (HR). Final efficacy analysis of GEICAM 2001-03 study. J Clin Oncol 2006;24(18):37S-S
72. Steele N, Zekri J, Coleman R, et al. Exemestane in metastatic breast cancer: effective therapy after third-generation non-steroidal aromatase inhibitor failure. Breast 2006;15(3):430-6
73. Chin YS, Beresford MJ, Ravichandran D, Makris A. Exemestane after non-steroidal aromatase inhibitors for post-menopausal women with advanced breast cancer. Breast 2007;16(4):436-9
74. Carlini P, Michelotti A, Ferretti G, et al. Clinical evaluation of the use of exemestane as further hormonal therapy after nonsteroidal aromatase inhibitors in postmenopausal metastatic breast cancer patients. Cancer Invest 2007;25(2):102-5
75. Gennatas C, Michalaki V, Carvounis E, et al. Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on letrozole or anastrozole. A phase II trial conducted by the Hellenic Group of Oncology (HELGO). Tumori 2006;92(1):13-7
76. Miller WR, Dixon JM. Antiaromatase agents: preclinical data and neoadjuvant therapy. Clin Breast Cancer 2000;1(Suppl 1):s9-14
77. Sourdaine P, Parker MG, Telford J, Miller WR. Analysis of the aromatase cytochrome P450 gene in human breast cancers. J Mol Endocrinol 1994;13:331-7
78. Colomer R, Monzo M, Tusquets I, et al. A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma. Clin Cancer Res 2008;14(3):811-6
79. Lønning PE, Knappskog S, Staalesen V, et al. Breast cancer prognostication and prediction in the postgenomic era. Ann Oncol 2007;18:1293-306
80. Lea OA, Kvinnsland S, Thorsen T. Improved measurement of androgen receptors in human breast cancer. Cancer Res 1989;49:7162-7
81. Ando S, DeAmicis F, Rago V, et al. Breast cancer: from estrogen to androgen receptor. Mol Cell Endocrinol 2002;193(1-2):121-8
82. Segaloff A, Meyer KK, Cuningha.M, Weeth JB. Hormonal therapy in cancer of breast.23. Effect of 7alpha-methyl-19-nortestosterone acetate + testosterone propionate on clinical course + hormonal excretion. Cancer 1964;17(10):1248
83. Nevinny HB, Haines CR, Dederick MM, Hall TC. Comparative study of 6-dehydro-17alpha-methyltestosterone + testosterone propionate in human breast cancer. Cancer 1964;17(1):95-&
84. Macedo LF, Guo ZY, Tilghman SL, et al. Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole. Cancer Res 2006;66(15):7775-82
85. Suzuki T, Miki Y, Moriya T, et al. 5 alpha-reductase type 1 and aromatase in breast carcinoma as regulators of in situ androgen production. Int J Cancer 2007;120(2):285-91
86. Geisler J, Ekse D, Lønning P. The aromatase inactivator exemestane (Aromasin) decreases plasma leptin levels in postmenopausal breast cancer patients. Proc Am Ass Cancer Res 2006;47:#420, 98
87. Jones S, Vogel C, Arkhipov A, et al. Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. J Clin Oncol 1999;17(11):3418-25
88. Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. J Clin Oncol 2000;18:1399-411
89. Paridaens R, Dirix L, Lohrisch C, et al. Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol 2003;14(9):1391-8
90. Paridaens R, Therasse P, Dirix L, et al. First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts) - a randomized phase III trial of the EORTC Breast Group (abstract 515]. Am Soc Clin Oncol 2004;6
91. Forbes JF, Cuzick J, Buzdar A, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008;9(1):45-53
92. Coates AS, Keshaviah A, Thurlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update of study BIG 1-98. J Clin Oncol 2007;25(5):486-92
93. Goss PE, Ingle JN, Pater JL, et al. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol 2008
94. Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005;366(9484):455-62
95. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350(11):1081-92
96. Coombes RC, Kilburn LS, Snowdon CF, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomized controlled trial. Lancet 2007;369(9561):559-70
97. Jakesz R, Greil R, Gnant M, et al. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J Natl Cancer Inst 2007;99(24):1845-53
98. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCICCTG MA.17. J Natl Cancer Inst 2005;97(17):1262-71
99. Group AT. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008;9(1):45-53
100. Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353(26):2747-57
101. Powles TJ, Hickish T, Kanis JA, et al. Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996;14:78-84
102. Coleman RE, ATACT. Effect of anastrozole on bone mineral density: 5-year results from the arimidex, tamoxifen, alone or in combination trial. J Clin Oncol 2006;24(Suppl 18S):5s
103. Coleman R, Banks L, Girgis S, et al. Skeletal effects of exemestane on bone-mineral density bone biomarkers and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol 2007;8(2):119-27
104. Perez EA, Jesse RG, Pritchard KI, et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCICCTG MA.17. J Clin Oncol 2006;24(22):3629-35
105. Lønning PE, Geisler J, Krag LE, et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 2005;23(22):5126-37
106. Geisler J, Lønning PE. Aromatase inhibitors as adjuvant treatment of breast cancer. Crit Rev Oncol Hematol 2006;57:53-61
107. Geisler J, Lønning PE, Krag LE, et al. Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomised, placebo-controlled study. Eur J Cancer 2006;42(17):2968-75
108. Gnant MFX, Mlineritsch B, Luschin-Ebengreuth G, et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 2007;25(7):820-8
109. Lohrisch C, Paridaens R, Dirix LY, et al. No Adverse Impact on Serum Lipids of the Irreversible Aromatase Inactivator Aromasin (R) (Exemestane (E)) in 1st Line Treatment of Metastatic Breast Cancer (MBC): Companion Study to a European Organization of Research and Treatment of Cancer (Breast Group) Trial with Pharmicias' Upjohn. Proc Am Soc Clin Oncol 2001;20:43a
110. Atalay G, Dirix L, Biganzoli L, et al. The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'. Ann Oncol 2004;15(2):211-7
111. Helle SI, Holly JMP, Tally M, et al. Influence of treatment with tamoxifen and change in tumor burden on the IGF-system in breast cancer patients. Int J Cancer (Pred Oncol) 1996;69:335-9
112. Wasan KM, Goss PE, Pritchard PH, et al. The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). Ann Oncol 2005;16(5):707-15
113. Morales L, Pans S, Paridaens R, et al. Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging. Breast Cancer Res Treat 2007;104(1):87-91
114. Lindgren P, Jonsson B, Redaelli A, Radice D. Cost-effectiveness analysis of exemestane compared with megestrol in advanced breast cancer: a model for Europe and Australia. Pharmacoeconomics 2002;20(2):101-8
115. Lundkvist J, Wilking N, Holmberg S, Jonsson L. Cost-effectiveness of exemestane versus tamoxifen as adjuvant therapy for early-stage breast cancer after 2-3 years treatment with tamoxifen in Sweden. Breast Cancer Res Treat 2007;102(3):289-99
116. Risebrough NA, Verma S, Trudeau M, Mittmann N. Cost-effectiveness of switching to exemestane versus continued tamoxifen as adjuvant therapy for postmenopausal women with primary breast cancer. Cancer 2007;110(3):499-508
117. Skedgel C, Rayson D, Dewar R, Younis T. Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen-exemestane and upfront anastrozole. Breast Cancer Res Treat 2007;101(3):325-33
118. Thompson D, Taylor DCA, Montoya EL, et al. Cost-effectiveness of switching to exemestane after 2 to 3 years of therapy with tamoxifen in postmenopausal women with early-stage breast cancer. Value Health 2007;10(5):367-76
119. Lønning PE. Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2-3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast cancer. Ann Oncol 2006;17(2):217-25